<abstract xmlns="http://www.w3.org/1999/xhtml">

<bold>Introduction</bold>: Despite the important role of general KRAS mutational status in the selection of an adequate therapeutic protocol in patients with colorectal cancer (CRC), studies that focus on its specific mutations and their significance on progression of disease are scarce. This study aimed to determine the significance of specific KRAS mutations in response to standard chemotherapy protocols with oxaliplatin-based (FOLFOX 4, OXFL) in the first-line and irinotecan-based chemotherapy (FOLFIRI, IFL) in the second-line therapy, and to evaluate the correlation between these mutations and clinicopathological characteristics of CRC patients.
<bold>Methods</bold>: Genomic DNA was extracted from the FFPE tumour tissue sections while the KRAS mutation test was performed by using PCR methods.
<bold>Results</bold>: Prevalence of KRAS gene mutations in CRC patients was 45%. Mutated KRAS was more frequent in later stages of tumor infiltrations (P =0.0017), on the right side of the colon (P= 0.0044), and in patients who developed metastases in the first 6 months after CRC diagnosis than in patients who developed metastases after 24 months (P=0.0083). In a group of patients with a poor therapeutic response to standard chemotherapy the most frequent mutations in KRAS gene were G12D and G12V (63.88%), while in a group of patients with a good response to therapeutic protocols the most prevalent mutation was G12A (66.66%).
<bold>Conclusion</bold>: Our results indicate that there was a significant difference in biological behaviour between tumours harboring different mutations in KRAS gene. Overall, mutation G12A could be a novel prognostic biomarker for CRC patients treated with standard chemotherapy.
</abstract>

Introduction: Despite the important role of general KRAS mutational status in the selection of an adequate therapeutic protocol in patients with colorectal cancer (CRC), studies that focus on its specific mutations and their significance on progression of disease are scarce. This study aimed to determine the significance of specific KRAS mutations in response to standard chemotherapy protocols with oxaliplatin-based (FOLFOX 4, OXFL) in the first-line and irinotecan-based chemotherapy (FOLFIRI, IFL) in the second-line therapy, and to evaluate the correlation between these mutations and clinicopathological characteristics of CRC patients.
Methods: Genomic DNA was extracted from the FFPE tumour tissue sections while the KRAS mutation test was performed by using PCR methods.
Results: Prevalence of KRAS gene mutations in CRC patients was 45%. Mutated KRAS was more frequent in later stages of tumor infiltrations (P =0.0017), on the right side of the colon (P= 0.0044), and in patients who developed metastases in the first 6 months after CRC diagnosis than in patients who developed metastases after 24 months (P=0.0083). In a group of patients with a poor therapeutic response to standard chemotherapy the most frequent mutations in KRAS gene were G12D and G12V (63.88%), while in a group of patients with a good response to therapeutic protocols the most prevalent mutation was G12A (66.66%).
Conclusion: Our results indicate that there was a significant difference in biological behaviour between tumours harboring different mutations in KRAS gene. Overall, mutation G12A could be a novel prognostic biomarker for CRC patients treated with standard chemotherapy.

Mutations in the <italic>KRAS</italic> gene as a predictive biomarker of therapeutic response in patients with colorectal cancer

Laboratory for Immunology and Genetics, Center for Medical and Clinical biochemistry

Faculty of Medicine, Research Center for Biomedicine

Department of Biology and Ecology, Faculty of Science and Mathematics

Revista Romana de Medicina de Laborator

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Mutations in the  gene as a predictive biomarker of therapeutic response in patients with colorectal cancer

Introduction: Despite the important role of general KRAS mutational status in the selection of an adequate therapeutic protocol in patients with colorectal...

Mutations in the KRAS gene as a predictive biomarker of therapeutic response in patients with colorectal cancer

Pubblicato online: 22 ott 2021

Pagine: 365 - 375

Ricevuto: 06 ott 2021

Accettato: 11 ott 2021

DOI: https://doi.org/10.2478/rrlm-2021-0035

Parole chiave
colorectal cancer, biomarker, real-time PCR, KRAS gene

© 2021 Dragana Jugović et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Mutations in the KRAS gene as a predictive biomarker of therapeutic response in patients with colorectal cancer

Pubblicato online: 22 ott 2021

Pagine: 365 - 375

Ricevuto: 06 ott 2021

Accettato: 11 ott 2021

DOI: https://doi.org/10.2478/rrlm-2021-0035

Parole chiavecolorectal cancer, biomarker, real-time PCR, KRAS gene

© 2021 Dragana Jugović et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Parole chiave
colorectal cancer, biomarker, real-time PCR, KRAS gene